You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development and validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 103

    Project Summary Sanfilippo disease (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologic: slowing of development, severe behavioral problems, progressive cognitive decline, dementia, and decline in motor skills leading to immobility, unresponsiveness, and death. We have focused on MPS IIID cause ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. An Automated Early Motor Development Risk Screener from Observational Video Recordings of Infants and Toddlers

    SBC: BSOLUTIONS, INC.            Topic: NICHD

    Motor development plays a pivotal role in an infant’s overall development and has a cascading effect on social, cognitive, memory, and language ability. These functions can be compromised when motor development is disrupted; motor disruption is associated with generalized developmental delays. Early screening and identification of delays can allow early interventions with the goal of not just im ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Topic 343- Cognitive Assessment and Monitoring Platform For Integrative Research (CAMPFIRE II)

    SBC: CHARLES RIVER ANALYTICS, INC.            Topic: NCI

    Cancer survivors commonly report cognitive impairments following chemotherapy. With a growing number of cancer survivors comes an increased urgency to better understand the precise etiology and prevalence of cognitive changes associated with cancer and cancer treatment. This pursuit is impeded by a lack of assessment tools that can accurately detect the full scope of cognitive deficits. To address ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma

    SBC: Syntrix Biosystems, Inc.            Topic: 102

    The chemokine receptors CXCR1 and CXCR2 (CXCR1/2) are validated as having essential roles in the growth, survival, motility, invasion and angiogenesis of human melanoma, which secretes abundant amounts of the corresponding chemokine ligands, including CXCL8. Additionally, abnormal cancer-induced immunosuppressive myeloid-derived suppressor cells (MDSCs) in the circulation and tumor correlate with ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer

    SBC: PRECYTE INC            Topic: 102

    Project Summary. The Indicator Cell Assay Platform (iCAP) is an inexpensive blood-based assay that can be used for early detection of disease, disease stage stratification, prognosis and response to therapy for a variety of diseases. The iCAP uses cultured, standardized cells as biosensors, capitalizing on the ability of cells to respond to disease signals present in serum with exquisite sensitivi ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation

    SBC: ADVANTAGENE, INC            Topic: 102

    DESCRIPTION (provided by applicant): Pancreatic adenocarcinoma has a dismal 5-year survival of andlt;5%. The only potential curative treatment is resection, but this is achieved in andlt;20% of patients and most still die due to micrometastases or residual disease. Patients with unresectable disease receive palliative chemotherapy with a median survival of less than 11 months. This application pro ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Prediction of Emergent SCIENce and Technology (PRESCIENT)

    SBC: Systems & Technology Research LLC            Topic: DTRA162005

    We propose to develop Prediction of Emergent SCIENce & Technology (PRESCIENT), a system that mines a text corpus of scientific patents and publications to discover emerging technologies that may impact WMD or CWMD. PRESCIENT will take as input patents and

    SBIR Phase II 2018 Department of DefenseDefense Threat Reduction Agency
  8. NNCI Synapse: Development of a Mobile Application to Disseminate Neuroscience Training to Medical Professionals

    SBC: C4 Innovations, LLC            Topic: 102

    While biological models of mental illness once emphasized “chemical imbalances,” modern perspectives increasingly incorporate a more nuanced understanding of genetics and epigenetics, neurotransmitters and neuroplasticity, and the functional dynamics of neural circuits. Yet despite extraordinary advances in neuroscience that have dramatically enhanced our understanding of the brain and of the ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Interstitial Intensity Modulated Photodynamic Therapy Phase II

    SBC: SIMPHOTEK, INC.            Topic: 102

    Photodynamic therapy (PDT) is a cancer treatment that utilizes visible or near-infrared light to activate a light- sensitive drug (photosensitizer, PS) that, in turn, creates reactive singlet oxygen species from ground triplet state oxygen that is present in the tumor. The resulting reactive products induce tissue death. Ideally the reactive species will be produced within only the target volume, ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. A game-based intervention for Opioid Use Disorder

    SBC: Pear Therapeutics, Inc.            Topic: NIDA

    PROJECT SUMMARY/ABSTRACT Opioid Use Disorder (OUD) is a key driver of the current opioid epidemic in the United States. Nearly 80% of individuals with OUD do not receive treatment. Buprenorphine Medication Assisted Treatment (MAT) is an effective form of care for OUD. Buprenorphine ameliorates craving and withdrawal, and reduces illicit opioid use, mortality, and problems associated with drug use. ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government